Regenxbio (RGNX) Misses Q3 EPS by 29c; Reports $533.5M of Cash and Cash Equivalents
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights
November 2, 2021 4:05 PM EDTROCKVILLE, Md., Nov. 2, 2021 /PRNewswire/ --
Announced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise REGENXBIO to receive $370 million upfront payment Transaction expected to close by end of 2021, subject to satisfaction of customary closing conditions, including applicable regulatory approvals Presented positive initial data from RGX-314 Phase II trials for the treatment of wet AMD and diabetic retinopathy using in-office suprachoroidal delivery  ... More